Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis
University of Kansas Medical Center
Summary
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.
Description
This is a randomized, placebo-controlled, parallel group clinical trial in those those with CF on elexacaftor/tezacaftor/ivacaftor to determine if treatment with losartan improves response to modulator therapy using sweat chloride as an marker of CFTR function.
Eligibility
- Age range
- 12+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Established diagnosis of cystic fibrosis * Age 12 years and older * Stable use of elexacaftor/tezacaftor/ivacaftor for 90 days prior to enrollment * Sweat chloride concentration 50 mmol/L or greater while on elexacaftor/tezacaftor/ivacaftor Exclusion Criteria: * Prior lung transplant * BMI \<18 * CF pulmonary exacerbation requiring hospitalization or intravenous antibiotics in the preceding 30 days * Systemic corticosteroid or regular non-steroidal anti-inflammatory use in the preceding 30 days * Chronic use of angiotensin receptor blockers or angiotensin converting en…
Interventions
- DrugLosartan
Treatment with losartan through week 12
- DrugPlacebo
Treatment with placebo through week 12
Location
- University of Kansas Medical CenterKansas City, Kansas